Strengthening Verification Systems Over Competing for Results
Recent moves by health authorities and audit agencies are converging on a direction that prioritizes improving verification systems over simply expanding technology adoption. The Ministry of Food and Drug Safety’s certification for outstanding AI digital medical device companies grants review privileges to firms whose development capabilities have been confirmed, while still leaving them responsible for proving effectiveness after the fact. Criticism over duplicated construction and poor quality in public AI training data, as well as administrative sanctions for violations in clinical trial management, all fall within the same trend.
This change reflects a stronger belief that as industries grow rapidly, the reliability of data and clinical operations becomes the foundation of competitiveness. Going forward, it will be harder to differentiate based solely on the speed of launching technology first, while companies equipped with standardized data management and clinical quality assurance are likely to gain an advantage in regulatory response and business expansion.
Where the Bottleneck in New Drug Development Has Shifted
In new drug development, execution capability in the later stages of clinical trials and just before approval is emerging as a bigger turning point than the earlier stage of identifying candidate substances. Overseas, AI-designed candidates have entered Phase 3 clinical trials in China, and there have even been cases of successful Phase 3 trials for mRNA cancer therapeutics. On the other hand, there have also been cases where the approval process was halted solely because of manufacturing and quality-control issues.
Domestic companies are also advancing a variety of pipelines into clinical trials, including obesity, Alzheimer’s disease, and immuno-oncology, but the competitive focus is now shifting away from merely expanding indications toward actual patient convenience, production consistency, and the sustainability of follow-up development. For example, bofanglutide aims to improve medication adherence by extending dosing intervals, while approval of the Phase 1 clinical trial plan for PADIVAX can be read as an attempt to expand a vaccine platform into degenerative diseases. Yet such efforts can only secure meaningful value if they are backed by capabilities in clinical design and quality control.
Why Platform Technologies Are Becoming More Valuable
In the area of hard-to-treat diseases, the importance of platform technologies—such as delivery systems, models, and co-development structures—is growing more than that of any single candidate substance. As failures continue in DMD therapeutics, HLB Panagene is seeking to solve the challenge through a PNA-AOC-based delivery strategy. KAIST’s BBTB chip has presented a tool for predicting brain tumor treatment responses by patient, while Seoul St. Mary’s Hospital has expanded an international collaboration framework that divides discovery and validation through the Korea-U.S. innovation outcome creation R&D project.
This trend shows the reality that it has become difficult for individual companies or laboratories to solve every stage on their own. To raise the likelihood of success, it is no longer enough for the candidate substance itself to be excellent; developers must also design which disease to target, which delivery method to use, and which validation model to combine. As a result, the center of research and development is shifting from one-off achievements to reusable foundational technologies.
The Scientific Advancement of Beauty and Biomanufacturing Sites
Even in manufacturing settings, quality control is evolving from a focus on final inspection to a direction of monitoring the entire process in real time. COSMAX is seeking to use the Pohang Light Source accelerator to precisely analyze cosmetic ingredient delivery and structural changes, while Wuxi Kolmar became the first overseas plant to be recognized as meeting domestic-level manufacturing and quality-control standards. The semiconductor ultrapure water elemental analysis device UA-1001 and GC Biopharma’s stability evaluation of an mRNA-LNP vaccine show that in both the bio and materials industries, analytical technology is directly tied to business competitiveness.
Behind this is the view that in the global market, it has become difficult to sustain a premium based solely on brand power or production capacity. As seen in Sulwhasoo’s push into Japan, even in consumer goods, supporting a premium image now requires not only broader distribution but also scientific explanatory power regarding efficacy, stability, and manufacturing consistency. Ultimately, investment in research equipment and quality systems is becoming a core asset for export competitiveness.